

Key Trend Shaping the RSV Therapeutics Market in 2025: Pfizer's Abrysvo Approval Marks A Significant Advancement Market

The Business Research Company's RSV Therapeutics Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, May 23, 2025

[/EINPresswire.com/](https://EINPresswire.com/) -- What Recent Market Growth Indicates About the Future of RSV Therapeutics?

The respiratory syncytial virus RSV therapeutics market has been witnessing remarkable growth in recent years. It has risen exponentially from \$1.6 billion in 2024 to an estimated \$2 billion in 2025, recording a strong compound annual growth rate CAGR of 25.0%. This significant growth in



The Business Research Company's Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts Through 2034"

The Business Research Company

the historic period can be accredited to increased disease awareness, advancements in virology, pediatric vulnerabilities to the disease, epidemic outbreaks, and progressive development in vaccine production.

How Will the RSV Therapeutics Market Evolve Over the Next Years?

The market size for RSV therapeutics is projected to continue an upward trend and grow to \$4.59 billion in 2029, with an expected compound annual growth rate CAGR of 23.1%. The robust growth forecasted can be

attributed to the innovation in biologic therapies, the emergence of new antivirals, a heightened focus on the elderly population, and embrace of maternal immunization strategies. The collaborations in global research are also a significant factor. Key trends influencing the market include advancements in monoclonal antibodies, a rise in nasal vaccines and delivery systems, an increase in combination therapies, the invention of novel drug delivery systems, and emerging home-based treatment options.

Get Your Free Sample Market Report:

The Business
Research Company

The Business Research Company



What Is Driving the Growth of the RSV Therapeutics Market?

Increased prevalence of RSV infection poses a serious global health concern, driving market growth. Known for causing mild to severe respiratory infections, RSV predominantly affects newborns, young children, elderly adults, and individuals with compromised immune systems. As the occurrences of RSV infections rise, so does the need for innovative treatments to mitigate the severity of RSV-related complications. This scenario prompts substantial growth in the RSV therapeutics market.

Who Are the Key Players in the Market?

Major companies steering the RSV therapeutics market comprise Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc., Gilead Sciences Inc., Moderna Inc., Regeneron Pharmaceuticals Inc., Novavax AB, Vir Biotechnology Inc., Lupin Limited, Kyorin Pharmaceutical Co. Ltd.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/respiratory-syncytial-virus-rsv-therapeutics-global-market-report>

What Emerging Trends are Noted in the RSV Therapeutics Market?

There is a profound trend towards the development of new drugs and vaccines with greater efficacy in the RSV therapeutics market. The key industry players adopt innovative R&D strategies around these aspects to maintain a robust foothold in the market.

How is the RSV Therapeutics Market Segmented?

The market for RSV therapeutics has been segmented based on different factors such as:

- 1 By Drug: Palivizumab, Ribavirin, Other Drugs
- 2 By Treatment: Immune Prophylaxis, Supportive Care, Antiviral Medications
- 3 By Dosage Form: Oral, Injectable, Other Dosage Forms
- 4 By Patient Type: Pediatrics, Adults
- 5 By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

In terms of subsegments, there has been significant progress and the primary ones are:

- 1 By Palivizumab: Monoclonal Antibody
- 2 By Ribavirin: Antiviral Medication
- 3 By Other Drugs: Cidofovir, Nitazoxanide, Other Experimental Or Off-Label Treatments.

What are the Regional Insights of RSV Therapeutics Market?

In 2024, North America stood as the largest contributor to the RSV therapeutics market. However, during the forecast period, Asia Pacific is predicted to be the fastest-growing region. The report's coverage extends to regions including Asia-Pacific, Western Europe, Eastern Europe,

North America, South America, Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:

Respiratory Devices And Equipment (Therapeutic And Diagnostic) Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-therapeutic-and-diagnostic-global-market-report>

Respiratory Disposables Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/respiratory-disposables-global-market-report>

Respiratory Devices And Equipment (Therapeutic) Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-therapeutic-global-market-report>

The Business Research Company offers more such comprehensive studies with data-rich insights for your needs. Learn more about our wide array of reports covering 27 industries across 60+ geographies. We take pride in our 1,500,000 datasets, in-depth secondary research, and exclusive inputs from industry leaders. Stay informed and ahead of the competition with our resources.

Reach the Business Research Company at: <https://www.thebusinessresearchcompany.com/>

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Or write to us at info@tbrc.info

Follow us on LinkedIn: <https://in.linkedin.com/company/the-business-research-company> and on

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxICpgmyFQ. Explore our Global

Market Model at <https://www.thebusinessresearchcompany.com/global-market-model>.

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/815418409>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something

we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.